Skip to main content
Astellas Pharma Inc. logo

Astellas Pharma Inc. — Investor Relations & Filings

Ticker · 4503 ISIN · JP3942400007 LEI · 529900IB708DY2HBBB35 T Manufacturing
Open in API
Filings indexed 78 across all filing types
Latest filing 2026-05-26 Investor Presentation
Country JP Japan
Listing T 4503

About Astellas Pharma Inc.

https://www.astellas.com/en

Astellas Pharma Inc. is a global pharmaceutical company dedicated to improving human health by turning innovative science into value for patients. The company's core activities encompass the research, development, manufacture, and commercialization of novel pharmaceutical products. Astellas focuses on pioneering transformative therapies in disease areas with high unmet medical needs, including oncology, ophthalmology, urology, immunology, and women's health. Through its patient-centric approach and robust research and development programs, the company aims to deliver innovative healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
経営企画2026説明会資料（中期経営計画）
Investor Presentation Classification · 89% confidence The document is a slide‐style presentation entitled “経営計画2026” (Management Plan 2026) by Astellas Pharma’s CEO, containing strategic objectives, financial forecasts, R&D pipeline charts, capital allocation plans, and governance overview. It does not contain full audited financial statements or earnings results, nor is it merely a brief factsheet or notice. The detailed slide format and forward‐looking strategy confirm it as an investor presentation.
2026-05-26 Japanese
より大きな「価値」をより速く届ける持続可能な成長を実現する経営計画2026（対象期間：2026年度～2030年度）を策定
Investor Presentation Classification · 75% confidence The document is a corporate press release announcing Astellas’s mid-term management plan (“経営計画2026”) for 2026–2030, detailing strategic objectives, financial targets, growth drivers, pipeline milestones, and shareholder return policy. It is not an earnings announcement or an official annual/interim financial report, nor is it simply a link or certification. Rather, it provides an in-depth strategic presentation aimed at investors, covering financial strategy, market positioning, and forward-looking goals, which aligns with the definition of an Investor Presentation (IP).
2026-05-26 Japanese
訂正発行登録書
Capital/Financing Update Classification · 82% confidence The document is a correction to an issuance registration statement (訂正発行登録書) filed with the Kanto Finance Bureau for corporate bond issuance (社債). It provides details on the registration, issuance limits, effective dates, and references an earlier registration. This constitutes a financing update regarding the company’s debt issuance. It is not an earnings release, annual report, or management change notice. The most fitting category is Capital/Financing Update (CAP).
2026-05-14 Japanese
臨時報告書
Regulatory Filings Classification · 90% confidence The document is a Japanese 臨時報告書 (“timely report”) filed under the Financial Instruments and Exchange Act for a material event (impairment loss on affiliate shares), not an AGM, annual or interim report, earnings release, dividend notice, or any other specific category. It is a regulatory disclosure of a corporate event. Our taxonomy lacks a dedicated “timely report” type, so it defaults to the general “Regulatory Filings” category (RNS).
2026-04-27 Japanese
無形資産の減損損失および個別決算（日本基準）における 特別損失の計上について
Regulatory Filings
2026-04-27 Japanese
2026年３月期 決算説明会資料
Regulatory Filings
2026-04-27 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.